Literature DB >> 14614366

Effect of the preschool pertussis booster on national notifications of disease in Australia.

Siranda Torvaldsen1, Peter B McIntyre.   

Abstract

BACKGROUND: Australia introduced a fifth dose of pertussis vaccine at 4 to 5 years of age in 1994, the first country to do so for some 40 years. We report trends in national pertussis notifications from 1993 to 2001.
METHODS: Notified pertussis cases were analyzed by age and year of disease onset.
RESULTS: Before the fifth dose was introduced, notification rates were higher among 5- to 9-year-olds than 10- to 14-year-olds (76 per 100 000 population vs.65 per 100 000). As more 5- to 9-year-olds became eligible for the fifth dose, their notification rates as a group and by year of age progressively fell to below those of 10- to 14-year-olds, consistent with a vaccine effect. Comparison of notification rates for the epidemic years of 1997 and 2001 shows that 5- to 10-year-olds (eligible for fifth dose) had lower notification rates in 2001 (61 per 100 000) than 5- to 10-year-olds in 1997 (196 per 100 000). This contrasts with children who were not eligible for the fifth dose (12- to 14-year-olds), who had higher notification rates in 2001 (223 per 100 000) than 12- to 14-year-olds in 1997 (160 per 100 000).
CONCLUSIONS: The pattern of age-specific notification rates provides strong evidence that the fifth dose reduced the incidence of pertussis in older children. It will be important to track the impact of the fifth dose on adolescent pertussis notifications to assess the duration of vaccine-acquired immunity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614366     DOI: 10.1097/01.inf.0000095198.75170.b6

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  6 in total

1.  The impact of adolescent pertussis immunization, 2004-2009: lessons from Australia.

Authors:  Helen E Quinn; Peter B McIntyre
Journal:  Bull World Health Organ       Date:  2011-07-05       Impact factor: 9.408

2.  Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine.

Authors:  Roland Sänger; Ulrich Behre; Karl-Heinz Krause; Hans-Peter Loch; Peter Soemantri; Dietmar Herrmann; Eugenie Schmitz-Hauss; Joanne Wolter; Bernard Hoet
Journal:  Eur J Pediatr       Date:  2007-01-18       Impact factor: 3.183

3.  Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia.

Authors:  Patricia Campbell; Peter McIntyre; Helen Quinn; Linda Hueston; Gwendolyn L Gilbert; Jodie McVernon
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

4.  Clinical presentation of pertussis in fully immunized children in Lithuania.

Authors:  Irena Narkeviciute; Ema Kavaliunaite; Genovaite Bernatoniene; Rimantas Eidukevicius
Journal:  BMC Infect Dis       Date:  2005-05-27       Impact factor: 3.090

5.  Prevention of pertussis: from clinical trials to Real World Evidence.

Authors:  S Esposito
Journal:  J Prev Med Hyg       Date:  2018-09-28

6.  Serologic evidence of pertussis infection in vaccinated Iranian children.

Authors:  Anahita Sanaei Dashti; Abdollah Karimi; Reza Arjmand; Mohsen Moghadami; Taherh Kheirkhah; Farideh Shiva; Zari Gholinejad; Hassan Joulaei
Journal:  Iran J Med Sci       Date:  2012-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.